Espinoza Octavio reported option exercise involving 972 shares of LIGAND PHARMACEUTICALS INC at $52.84 for $51.4k on May 27, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Financial Officer
Chief Financial Officer
Filed May 28, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$51,360.48Shares × reported price
Shares traded
972Common Stock
Price per share
$52.84Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
27,679Direct
Trade date
May 27, 2026Option exercise
Filed
May 28, 2026, 7:43 PM ET1-day reporting delay
Accession
0002001011-26-000071Code M · Transaction 387810
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
May 27, 2026Option exercise972$0.00$0Trade 387811
May 27, 2026Option exercise764$0.00$0Trade 387812
May 27, 2026Option exercise764$63.62$48,605.68Trade 387809
4 transaction rows in this filing. Joint filers share the same rows.

LGND price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
LGND · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +3%1w ago −7.2%1d ago +0.3%
Returns since7d +0.5%30d +29%90d +23%180d1y

Footnotes in full

F1: The stock option vests as to approximately 55% of the underlying shares in 12 substantially equal monthly installments beginning on January 5, 2025, and approximately 45% of the underlying shares in two substantially equal monthly installments thereafter. F2: Grant to reporting person of stock options that will vest and become exercisable over a 4-year period measured from December 5, 2022, with 12-1/2% of the shares subject to the stock options vesting on the date that is six months after December 5, 2022 and the remaining stock options vesting in 42 equal monthly installments thereafter.